ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Business

Japan's Otsuka applies to FDA for schizophrenia smart pill

TOKYO -- Japanese drugmaker Otsuka Pharmaceutical is seeking U.S. regulatory approval to market a schizophrenia treatment that incorporates a sensor designed to ensure patients take their medicine.

     The ingestible sensor was developed by the U.S. startup Proteus Digital Health, which forged an alliance with Otsuka in 2012 to collaborate in the field of central nervous system medications. The core Otsuka Holdings unit announced Friday that it has applied to the U.S. Food and Drug Administration for approval to make and sell a formulation of its Abilify schizophrenia drug.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more